Semiautomatic Aerosol Propellant Filler
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The contract request involves the procurement of a Semiautomatic Aerosol Propellant Filler designed for pMDI two-stage formulation, intended to support advanced pharmaceutical manufacturing and inhalation drug delivery research conducted by the FDA’s Center for Drug Evaluation and Research. This procurement includes not only the purchase of the equipment but also its delivery, installation, validation support, training, and warranty services. The solicitation follows streamlined FAR commercial acquisition procedures and incorporates specific clauses available through Acquisition.gov. Interested vendors must provide quotations by June 22, 2026, with all inquiries directed in writing to the designated FDA contact by June 15, 2026. The solicitation package includes detailed documentation such as the Statement of Work, Pricing Schedule, Past Performance Reference Form, and Brand Name or Equal Compliance Matrix, among others. The award will be managed out of the FDA’s office in Rockville, Maryland, with the place of performance in Silver Spring, Maryland. The procurement has no set-aside restrictions and falls under NAICS code 333914, covering machinery manufacturing. All submissions and communications are handled electronically through the provided FDA points of contact.
General Info
Agency
NAICS
Place of Performance
Silver Spring, MD, 20993, USASet-Aside
Timeline
Response Deadline
Organization & Contact Information
Full Description
Semiautomatic Aerosol Propellant Filler for pMDI Two-Stage Formulation
Brand Name or Equal
This is a Request for Quotation (RFQ) for commercial products prepared in accordance with FAR Part 12 and FAR Part 13 procedures utilizing the FAR Revolutionary FAR Overhaul clauses and provisions available at Acquisition.gov.
The U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Office of Testing and Research (OTR), requires the purchase, delivery, installation, validation support, training, and warranty of a Semiautomatic Aerosol Propellant Filler for pMDI Two-Stage Formulation. The requirement supports FDA research in advanced pharmaceutical manufacturing and inhalation drug delivery systems.
Please refer to the following attachments for all the pertinent details of this requirement
Attachment I Statement of Work (SOW)
Attachment II Pricing Schedule
Attachment III Past Performance Reference Form
Attachment IV SF-18 Request for Quotations
Attachment V Brand Name or Equal Compliance Matrix
Attachment VI Buy American Certificate
Attachment VII Solicitation Document
Submit all questions in writing via email to Michele.Jackson@fda.hhs.gov no later than: June 15, 2026, at 9:00 AM Eastern Time
Questions received after this date may not receive a response.
Submit quotations electronically to Michele.Jackson@fda.hhs.gov no later than June 22, 2026, at 11:00 AM Eastern Time
Include in the Subject Line: [Company Name] – 75F40126Q00231/CDER-2026-133243 Quote